{"id":"NCT03603314","sponsor":"Sensorion","briefTitle":"Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss","officialTitle":"A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-02-15","primaryCompletion":"2021-11-04","completion":"2022-01-12","firstPosted":"2018-07-27","resultsPosted":"2023-03-01","lastUpdate":"2023-03-01"},"enrollment":115,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Severe Sudden Sensorineural Hearing Loss"],"interventions":[{"type":"DRUG","name":"SENS-401","otherNames":[]},{"type":"OTHER","name":"Placebo Oral Tablet","otherNames":[]},{"type":"DRUG","name":"SENS-401","otherNames":[]}],"arms":[{"label":"29 mg dose group","type":"EXPERIMENTAL"},{"label":"43.5 mg dose group","type":"EXPERIMENTAL"},{"label":"placebo oral tablet","type":"PLACEBO_COMPARATOR"}],"summary":"Primary objective of the study is to assess the efficacy of SENS-401 on hearing loss in comparison to placebo at the end of the 4-week treatment period","primaryOutcome":{"measure":"Change in Pure Tone Audiometry PTA (dB) (Average of the Hearing Threshold of the 3 Contiguous Most Affected Hearing Frequencies in dB as Identified at Study Entry) From Baseline to the End of Treatment Visit (Day 28 ± 3).","timeFrame":"28 days","effectByArm":[{"arm":"29 mg Dose Group","deltaMin":-27.754,"sd":null},{"arm":"43.5 mg Dose Group","deltaMin":-24.931,"sd":null},{"arm":"Placebo Oral Tablet","deltaMin":-25.214,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.3419"},{"comp":"OG001 vs OG002","p":"0.5181"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":26,"countries":["Bulgaria","Canada","Czechia","France","Germany","Israel","Serbia","Slovakia","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":38},"commonTop":["Constipation","Headache","Nausea","Vertigo","Hypertension"]}}